Ocular Therapeutix, Inc. (OCUL) Discusses Positive Top Line Results From SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD Transcript
Source: SeekingAlpha
2026-02-17 16:15:00 ET
Ocular Therapeutix, Inc. (OCUL) Discusses Positive Top Line Results From SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD February 17, 2026 8:00 AM EST...
Read the full article on Seeking Alpha
For further details see:
Ocular Therapeutix, Inc. (OCUL) Discusses Positive Top Line Results From SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD Transcript
Ocular Therapeutix Inc.
NASDAQ: OCUL
OCUL Trading
1.61% G/L:
$10.085 Last:
1,706,525 Volume:
$10.02 Open:
OCUL Latest News
March 09, 2026 04:01:00 pm
Ocular Therapeutix(TM) Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OCUL Stock Data
$2,007,118,202
193,092,608
0.71%
76
N/A
Biotechnology & Life Sciences
Healthcare
US
Bedford
